A transplant pharmacist looks at what azacitidine plus venetoclax’s event-free survival advantage over intensive chemotherapy means for induction selection, and why it doesn’t yet replace 7+3 or CPX-351.
In the phase 3 REGAL trial, galinpepimut-S reached a median overall survival of 24.0 months, compared with 14.7 months for best available treatment, in patients in second or later remission.
Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.
An analysis of 40 economic studies found PCV20 and PCV21 outperformed older strategies, while low uptake and racial gaps limited the benefit of vaccination.
Early germline BRCA testing identifies patients with metastatic pancreatic adenocarcinoma who can be considered for olaparib maintenance if their disease has not progressed after at least 16 weeks of first-line platinum chemotherapy.
A new US consensus on pancreatic enzyme replacement therapy in pancreatic cancer highlights how pharmacists can counsel patients on taking enzymes with food, check response early, and address barriers to filling the prescription.
Neladalkib received accelerated approval for adults with advanced ALK-positive NSCLC after specified prior therapies, supported by durable responses in the ALKOVE-1 trial.